Equities Analysts Issue Forecasts for Humanigen, Inc.’s Q4 2022 Earnings (NASDAQ:HGEN)

Humanigen, Inc. (NASDAQ:HGENGet Rating) – Analysts at Oppenheimer reduced their Q4 2022 earnings per share estimates for Humanigen in a report released on Tuesday, April 19th. Oppenheimer analyst K. Degeeter now anticipates that the company will post earnings of $0.22 per share for the quarter, down from their prior estimate of $0.23. Oppenheimer also issued estimates for Humanigen’s FY2023 earnings at $0.45 EPS.

Humanigen (NASDAQ:HGENGet Rating) last announced its quarterly earnings results on Monday, February 28th. The company reported ($0.53) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.09. Humanigen had a negative net margin of 6,582.73% and a negative return on equity of 4,882.88%. The business had revenue of $1.04 million for the quarter, compared to analyst estimates of $1.01 million.

Separately, Zacks Investment Research upgraded shares of Humanigen from a “sell” rating to a “hold” rating in a research note on Thursday, February 24th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $21.00.

Shares of HGEN opened at $2.29 on Wednesday. Humanigen has a 52 week low of $1.67 and a 52 week high of $23.53. The firm has a market cap of $149.60 million, a P/E ratio of -0.56 and a beta of -1.46. The firm’s 50-day simple moving average is $2.69 and its 200 day simple moving average is $4.10.

A number of hedge funds have recently modified their holdings of HGEN. Morgan Stanley grew its position in Humanigen by 1,884.6% during the 2nd quarter. Morgan Stanley now owns 128,841 shares of the company’s stock worth $2,239,000 after acquiring an additional 122,349 shares during the last quarter. Royal Bank of Canada grew its position in shares of Humanigen by 44.2% in the 2nd quarter. Royal Bank of Canada now owns 9,950 shares of the company’s stock valued at $172,000 after buying an additional 3,050 shares during the last quarter. Invesco Ltd. bought a new stake in shares of Humanigen in the 2nd quarter valued at about $260,000. Wells Fargo & Company MN grew its position in shares of Humanigen by 22.4% in the 2nd quarter. Wells Fargo & Company MN now owns 3,675 shares of the company’s stock valued at $64,000 after buying an additional 673 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Humanigen in the 3rd quarter valued at about $108,000. Institutional investors and hedge funds own 39.37% of the company’s stock.

In other Humanigen news, insider Dale Chappell purchased 1,000,000 shares of the stock in a transaction dated Friday, March 11th. The stock was bought at an average price of $3.00 per share, with a total value of $3,000,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Edward P. Jordan purchased 12,500 shares of the stock in a transaction dated Wednesday, March 2nd. The shares were acquired at an average cost of $2.32 per share, with a total value of $29,000.00. The disclosure for this purchase can be found here. Insiders have bought a total of 1,059,500 shares of company stock valued at $3,140,310 in the last three months. 27.30% of the stock is owned by insiders.

About Humanigen (Get Rating)

Humanigen, Inc, a clinical stage biopharmaceutical company, develops a portfolio of anti-inflammatory immunology and immuno-oncology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which has completed Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that is in Phase II clinical trial in patients with chronic myelomonocytic leukemia.

Further Reading

Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.